Drug recall · December 23, 2020
Azacitidine for Injection 100 mg/vial For Subcutaneous and Intravenous Use Only Single-Dose Vial recall
Why: cGMP deviations: Vials may not be sealed correctly affecting sterility.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Azacitidine for Injection 100 mg/vial For Subcutaneous and Intravenous Use Only Single-Dose Vial Manufactured by Shilpa Medicare Limited Jadcherla -509301 INDIA Distributed by: Cipla USA, Inc. 10 Independence Blvd, Suite 300 Warren, NJ 07059 NDC 69097-805-40
- Lots / codes
Lot #: 7S10182A, Ex 9/2021
- Quantity
- 2151 vials
- Company
- Cipla, Warren, NJ
- Distribution
- USA Nationwide
- Initiated
- December 14, 2020 · Voluntary: Firm initiated
- Classified
- December 16, 2020
- Reported
- December 23, 2020
- Ended
- August 16, 2022
- How notified
- Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Azacitidine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.